TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Brief Summary: Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.


Options:
A: Arm Label: total removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (total removal) | Arm Label: partial removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (partial removal) | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (total removal); Assigned to Arm(s): total removal | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (partial removal); Assigned to Arm(s): partial removal
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Corneal collagen | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham comparator | Intervention Type: PROCEDURE; Name: Corneal collagen; Assigned to Arm(s): Treatment | Intervention Type: PROCEDURE; Name: Sham comparator; Assigned to Arm(s): Control
C: Arm Label: Corneal Collagen Cross-linking (CXL) Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution, Device: UVA Irradiation | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution | Intervention Type: DRUG; Name: riboflavin ophthalmic solution; Assigned to Arm(s): Control Group, Corneal Collagen Cross-linking (CXL) Treatment Group | Intervention Type: DEVICE; Name: UVA Irradiation; Assigned to Arm(s): Corneal Collagen Cross-linking (CXL) Treatment Group
D: Arm Label: Corneal Collagen Cross-linking (CXL) Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution, Device: UVA Irradiation | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Drug: riboflavin ophthalmic solution | Intervention Type: DRUG; Name: riboflavin ophthalmic solution; Assigned to Arm(s): Control Group, Corneal Collagen Cross-linking (CXL) Treatment Group | Intervention Type: DEVICE; Name: UVA Irradiation; Assigned to Arm(s): Corneal Collagen Cross-linking (CXL) Treatment Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ErythroPOietin in Myocardial Infarction
Brief Summary: EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct size and cardiac remodeling in patients with acute myocardial infarction. Eligible patients will be randomly assigned to receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months later.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EPO | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EPO; Assigned to Arm(s): 1
B: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy
C: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% NaCl | Arm Label: verum; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin alfa | Intervention Type: DRUG; Name: recombinant human erythropoietin alfa; Assigned to Arm(s): verum | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (250ug Twice Daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients With Moderate to Severe Asthma
Brief Summary: The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler. The purpose of this study is to determine how well your asthma is controlled when taking one of the three treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FlutiForm 250/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SKP-Fluticasone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flovent Fluticasone HFA | Intervention Type: DRUG; Name: FlutiForm 250/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: SKP-Fluticasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Flovent Fluticasone HFA; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol Fumarate 100/10 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol Fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3
D: Arm Label: Symbicort "as needed"+placebo Pulmicort bid; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid | Arm Label: Pulmicort bid + terbutaline "as needed"; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonode bid + terbutaline 'as needed' | Intervention Type: DRUG; Name: budesonide/formoterol 'as needed' + budesonide placebo bid; Assigned to Arm(s): Symbicort "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: budesonode bid + terbutaline 'as needed'; Assigned to Arm(s): Pulmicort bid + terbutaline "as needed"

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.
Brief Summary: This study will assess clinical outcomes of extended weekly hours of haemodialysis (\>= 24 hours per week) compared with standard hours of haemodialysis (\<=18 hours/week) in people with ESKD.


Options:
A: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A
B: Arm Label: Bright Light Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Bright Light Therapy | Arm Label: Wait-list intervention; Type: OTHER; Interventions: Behavioral: Wait-list intervention | Intervention Type: BEHAVIORAL; Name: Bright Light Therapy; Assigned to Arm(s): Bright Light Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list intervention; Assigned to Arm(s): Wait-list intervention
C: Arm Label: extended hours; Type: EXPERIMENTAL; Interventions: Procedure: haemodialysis | Arm Label: standard hours; Type: ACTIVE_COMPARATOR; Interventions: Procedure: haemodialysis | Intervention Type: PROCEDURE; Name: haemodialysis; Assigned to Arm(s): extended hours, standard hours
D: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension
Brief Summary: To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.


Options:
A: Arm Label: The Red Heart Pill 2b (Polypill) (A); Type: EXPERIMENTAL; Interventions: Drug: Red Heart Pill 2b (Polypill) | Arm Label: Standard Practice Group (B); Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Practice | Intervention Type: DRUG; Name: Red Heart Pill 2b (Polypill); Assigned to Arm(s): The Red Heart Pill 2b (Polypill) (A) | Intervention Type: OTHER; Name: Standard Practice; Assigned to Arm(s): Standard Practice Group (B)
B: Arm Label: Caduet; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine besylate/atorvastatin calcium single pill combination | Intervention Type: DRUG; Name: Amlodipine besylate/atorvastatin calcium single pill combination; Assigned to Arm(s): Caduet
C: Arm Label: OM40/AML10; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine | Arm Label: OM40/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Drug: Hydrochlorothiazide | Arm Label: OM40/AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): OM40/AML10, OM40/AML10/HCTZ25, OM40/HCTZ25 | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10, OM40/AML10/HCTZ25 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10/HCTZ25, OM40/HCTZ25
D: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Messages to Increase Eye Examination Behavior
Brief Summary: The purpose of this project is to test two different types of health messages, one that is developed for a specific group (targeted) and the other that is more personalized to individuals (tailored), to see which is better at changing how often people have their eyes examined. We hypothesize that people who get the tailored messages will be more likely to get a dilated eye exam than people who receive the targeted messages.


Options:
A: Arm Label: Pt. 1 Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: Pt. 1 Supportive Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Pt. 1 Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): Pt. 1 Supportive Therapy
B: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: tailored newsletter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: targeted newsletter | Intervention Type: BEHAVIORAL; Name: tailored newsletter; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: targeted newsletter; Assigned to Arm(s): 2
D: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF
Brief Summary: Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups - receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo - in a 1:1:1 ratio.


Options:
A: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
C: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-acetylcysteine (NAC) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine (NAC); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction
Brief Summary: Trial design:

This Phase III, investigator-driven, randomised, placebo-controlled efficacy and safety study will compare the effects of Sitagliptin in combination with granulocyte-colony stimulating factor (Lenograstim, G-CSF) on the improvement of myocardial function in patients undergoing routine percutaneous coronary revascularisation for acute myocardial infarction (time from onset of infarction to intervention 2 to 24 hours). The primary objective of this study is to compare between a treatment of G-CSF plus Sitagliptin, (G-CSF/Sitagliptin treatment group, n=87) versus Placebo (control treatment group, n=87) in change of global myocardial function from baseline to 6 months of follow-up.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glargine | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): glargine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenograstim (GRANOCYTE)=GCSF, Drug: Sitagliptin (Januvia) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride (NaCl) 0.9 %, Drug: Gelatin | Intervention Type: DRUG; Name: Lenograstim (GRANOCYTE)=GCSF; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sitagliptin (Januvia); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride (NaCl) 0.9 %; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gelatin; Assigned to Arm(s): 2
D: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning
Brief Summary: This study will be the first large scale randomized study of remote ischemic preconditioning (RIPC) ever performed and will define the role of this novel therapy as a clinical tool. This study will also be the first to define preoperative gene expression profiles associated with poor postoperative outcomes in a control (SHAM) population of children undergoing cardiac surgery. Finally, the role of RIPC in modifying these gene expression profiles will be examined. Therefore, mechanistic insight into the proven ability of RIPC to improve markers of tissue injury, and the expected improvement in clinically relevant endpoints, will be examined.


Options:
A: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning (RIPC) | Intervention Type: OTHER; Name: remote ischemic preconditioning (RIPC); Assigned to Arm(s): remote ischemic preconditioning
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning (RIPC) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SHAM | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning (RIPC); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: SHAM; Assigned to Arm(s): 2
C: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: Remote ischemic preconditioning | Arm Label: Sham control; Type: SHAM_COMPARATOR; Interventions: Other: Sham Control | Intervention Type: OTHER; Name: Remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: OTHER; Name: Sham Control; Assigned to Arm(s): Sham control
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)
Brief Summary: Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.


Options:
A: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pemetrexed disodium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab; Assigned to Arm(s): 2
C: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
D: Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy

Answer: B